A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome

Early Phase 1

Completed

• Conditions: Female Patients With Behcet's Syndrome
• Interventions: Drug: Abatacept

• Registration Number: NCT01693640
• Lead Sponsor: NYU Langone Health

Brief Summary

Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients

Detailed Description

This will be an open label study, where 20 Behcet's patients with resistant oral ulcers and 10 with resistant genital ulcers will be enrolled (screen 40). After enrollment all patients will be followed for a month to document the number of oral and genital ulcers on their current regimen. Then all patients will receive abatacept for 6 months (evaluated at weeks 0, 2, 4, 8, 12, 16 and 24). Then the treatment will be stopped and they will be observed for the next 2 months, for a total of 9 month trial.

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-09-19
• Study First Submitted QC: 2012-09-24
• Study First Posted: 2012-09-26
• Primary Completion: 2018-12-28
• Study Completion: 2018-12-28
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-25
• Last Update Posted: 2019-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 3

Inclusion Criteria

Not provided

Exclusion Criteria

1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study drug.

2. Women who are pregnant or breastfeeding.

3. Women with a positive pregnancy test on enrollment or before administration of abatacept.

   Target Disease Exceptions [Include as applicable]

   • Any patients with systemic manifestations of Behcet's syndrome (Patients with eye, CNS, vascular involvement, gastrointestinal disease)
   • Patients who are already on other immunosuppressive medications (azathioprine, TNF inhibitors, other biologic agents, methotrexate, mycophenolate mofetil, cyclosporine, cyclophosphamide)

4. Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.

5. Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to Behcet's syndrome and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.

6. Female subjects who have had a breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory, or other diagnostic evaluations.

7. Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ.

8. Subjects who currently abuse drugs or alcohol.

9. Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.

10. Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.

11. Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.

12. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis, or bronchiectasis).

13. Subjects at risk for tuberculosis (TB).

14. Subjects must not be positive for hepatitis B surface antigen.

15. Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.

16. Subjects with any of the following laboratory values

17. Hemoglobin < 8.5 g/dL

18. WBC < 3000/mm3 (< 3 x 109/L)

19. Platelets < 100,000/mm3 (< 3 x 109/L)

20. Serum creatinine > 2 times the ULN

21. Serum ALT or AST > 2 times the ULN

22. Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.

23. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.

24. Any concomitant biologic DMARD.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
abatacept	Abatacept	-

Primary Outcome Measures

Name	Time	Method
ulcers	6 month treatment period	The primary endpoint is number of oral and genital ulcers (AUC) during the treatment period

Secondary Outcome Measures

Name	Time	Method
BSAS	6 months	Behcet's syndrome activity score (BSAS)
Genital ulcers	6 month treatment	Number of genital ulcers
Treatment failures	6 months	Number of patients who fail to complete 6 months (treatment failures)
Side Effects	6 months	Monitoring of side effects
Oral ulcer pain	6 months	Oral ulcer pain-Visual Analog Scale (VAS)
MDHAQ	6 months	Multidimensional health assessment questionnaire (MDHAQ)
BDCAF	6 months	Behcet's disease current activity form (BDCAF) scores

Trial Locations

Locations (1)

NYU Center for Musculoskeletal Care; 🇺🇸 New York, New York, United States